P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

• Tracy Clevenger,
• Jean Cheung,
• Fanny Krantz,
• Michael Gulrajani,
• Cynthia Nguyen,
• Miranda Luarca,
• Cecile Krejsa,
• Wayne P. Rothbaum,
• Todd Covey

Affiliations

Tracy Clevenger

1 Kartos Therapeutics, Inc., Redwood City, CA, United States

Jean Cheung

1 Kartos Therapeutics, Inc., Redwood City, CA, United States

Fanny Krantz

1 Kartos Therapeutics, Inc., Redwood City, CA, United States

Michael Gulrajani

1 Kartos Therapeutics, Inc., Redwood City, CA, United States

Cynthia Nguyen

1 Kartos Therapeutics, Inc., Redwood City, CA, United States

Miranda Luarca

1 Kartos Therapeutics, Inc., Redwood City, CA, United States

Cecile Krejsa

1 Kartos Therapeutics, Inc., Redwood City, CA, United States

Wayne P. Rothbaum

1 Kartos Therapeutics, Inc., Redwood City, CA, United States

Todd Covey

1 Kartos Therapeutics, Inc., Redwood City, CA, United States